CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
For beginners, compare index funds and mutual funds on cost, simplicity, and diversification to choose the easier path to investing.
24,324 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
In this edition of the Morning Minute, Saylor is back to buying, signaling renewed confidence in Bitcoin. We break do...
China’s May export surge points to resilient demand from the US and strong tech shipments. With Liberation Day approa...
An overlooked defense contractor pivots to AI, turning years of skepticism into a rising star in enterprise AI and de...
The White House has nominated Brian Johnson to head the CFPB, aiming to steer consumer protection policy as leadershi...
Anthropic unveils a $150 million fellowship to place 1,000 AI coaches with nonprofits for a year, funded as the compa...
Trading activity in the largest non-stablecoin crypto assets cooled to two-year lows as investors sit on the sideline...
SpaceX gears up for the largest IPO in history on Nasdaq, while a 1:1 tokenized SpaceX equity trades on Solana. Backp...
Artificial intelligence is tightening its grip on personal finance, delivering personalized tools and faster decision...
With his 80th birthday approaching, Trump orchestrates high-profile appearances and a major White House event to proj...
A luxury of near-new mileage becomes a liability if a dealer claims a major repair. This article breaks down what hap...
XRP surged about 9% on the session, lifting from roughly $1.10 to $1.24 as ETF inflows and a rising technical pattern...